TVTX - Company ID 0001438533
Travere Therapeutics, Inc. (TVTX) reported revenue of $490.73M for fiscal year 2025, as filed in its audited annual report with the SEC.
| Fiscal year | Revenue | Change |
|---|---|---|
| FY 2025 | $490.73M | +110.5% |
| FY 2024 | $233.18M | +60.5% |
| FY 2023 | $145.24M | +32.7% |
| FY 2022 | $109.46M | -17.0% |
| FY 2021 | $131.84M | -33.5% |
| FY 2020 | $198.32M | +13.1% |
| FY 2019 | $175.34M | +6.8% |
| FY 2018 | $164.25M | +6.0% |
| FY 2017 |
Travere Therapeutics, Inc. (TVTX) reported revenue of $490.73M for fiscal year 2025, as filed in its audited annual report with the SEC.
Between fiscal 2011 and fiscal 2025, Travere Therapeutics, Inc.'s revenue grew from $0.00 to $490.73M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $154.94M |
| +16.0% |
| FY 2016 | $133.59M | - |
| FY 2012 | $0.00 | - |
| FY 2011 | $0.00 | - |